N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

Abstract

wherein B, G, A, E, R1, R3, R4, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

1 . (canceled) 
     
     
         2 . A compound having the structure: 
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable salts thereof. 
     
     
         3 . A composition comprising a compound, or its pharmaceutically acceptable salt thereof, according to  claim 2  and a pharmaceutically acceptable diluent or carrier. 
     
     
         4 . A method of treating cancer that over-expresses HER2 in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound, or its pharmaceutically acceptable salt thereof, according to  claim 2 . 
     
     
         5 . The method of  claim 4 , wherein the cancer is breast cancer. 
     
     
         6 . The method of  claim 4 , wherein an anti-tumor agent is administered in combination. 
     
     
         7 . The method of  claim 6 , wherein the anti-tumor agent is an inhibitor of growth factor. 
     
     
         8 . The method of  claim 7 , wherein the inhibitor of growth factor is trastuzumab. 
     
     
         9 . The method of  claim 5 , wherein an anti-tumor agent is administered in combination. 
     
     
         10 . The method of  claim 9 , wherein the anti-tumor agent is an inhibitor of growth factor. 
     
     
         11 . The method of  claim 10 , wherein the inhibitor of growth factor is trastuzumab.